4.6 Article

Immune Reconstitution of Patients Who Recovered From Steroid-Refractory Acute Graft-Versus-Host Disease After Basiliximab Treatment

Related references

Note: Only part of the references are listed.
Article Hematology

Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis

Xiao-Dong Mo et al.

Summary: Basiliximab is safe and effective for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD). Combined therapy does not improve the treatment response and may increase the risk of infection. Various factors are associated with the therapeutic response, leading to the development of a prognostic scoring system.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Article Immunology

Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies

Meng-Zhu Shen et al.

Summary: The long-term efficacy of preemptive interferon-alpha therapy in acute myeloid leukemia patients following allogeneic hematopoietic stem cell transplantation was assessed. The results showed that preemptive interferon-alpha therapy could clear minimal residual disease persistently, prevent relapse, and improve long-term survival in patients.

FRONTIERS IN IMMUNOLOGY (2022)

Article Oncology

Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

Shuang Fan et al.

Summary: This study compared the efficacy of preemptive IFN-alpha therapy and DLI in t(8;21) AML patients following allo-HSCT and evaluated the appropriate method for patients with different levels of RUNX1-RUNX1T1 transcripts. The results showed that preemptive IFN-alpha therapy was more beneficial for patients with low-level and intermediate-level RUNX1-RUNX1T1, while clinical outcomes were comparable for patients with high-level RUNX1-RUNX1T1.

FRONTIERS IN ONCOLOGY (2022)

Article Multidisciplinary Sciences

Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life

Algirdas Grevys et al.

Summary: The variable region sequences of IgG antibodies significantly impact their cellular uptake, recycling, and degradation, as well as their binding to FcRn. Differences in charge patch also modulate binding and transport properties. Fc-engineering may improve FcRn binding and overcome unfavorable charge patches for longer plasma half-life.

ISCIENCE (2022)

Article Multidisciplinary Sciences

Basiliximab impairs regulatory T cell (TREG) function and could affect the short-term graft acceptance in children with heart transplantation

Jacobo Lopez-Abente et al.

Summary: The study found that basiliximab (BXM) reduces Treg counts and function in vitro by affecting their proliferation, Foxp3 expression, and IL-10 secretion capacity. In pediatric heart transplant patients, BXM-treated patients showed decreased Treg counts and a diminished Treg/Teff ratio at 6 months post-treatment, returning to baseline values by the end of the 12-month follow-up period. These findings suggest that using BXM could have detrimental effects on Tregs and may impair their protective role during the period of highest incidence of acute graft rejection.

SCIENTIFIC REPORTS (2021)

Article Immunology

Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation

Jing-Rui Zhou et al.

Summary: Reactivation of both cytomegalovirus and Epstein-Barr virus is common after hematopoietic stem cell transplantation and is associated with poor outcomes, including lower overall survival and leukemia-free survival rates. Co-reactivation of these viruses is also linked to prolonged viral duration and poor CD4+CD25+ T cell reconstitution post-transplantation.

FRONTIERS IN IMMUNOLOGY (2021)

Review Biology

Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation

Hany Elmariah et al.

Summary: Allogeneic HCT is the only potential curative therapy for hematologic diseases, but patients are profoundly immunocompromised initially. Immune reconstitution after HCT, especially with alternative donors like haploidentical and umbilical cord blood, can improve access to treatment. Despite challenges, interventions such as antimicrobial prophylaxis and graft manipulation are available to mitigate risks during the immunocompromised period.

LIFE-BASEL (2021)

Article Hematology

Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease

Da-Bin Ryu et al.

Summary: Ruxolitinib treatment in murine sclerodermatous GVHD model showed significantly reduced severity of scl-GVHD in skin, decreased effector cells and regulatory T cells, as well as suppressed production of IFN-y and MCP-1. This effect is mediated through inhibition of JAK-STAT signaling pathway.

EXPERIMENTAL HEMATOLOGY (2021)

Article Immunology

Kinetics of IgG subclasses and their effects on the incidence of infection after allogeneic hematopoietic stem cell transplantation

Shiro Koh et al.

Summary: The study investigated the impact of stem cell source on humoral immune reconstitution, including IgG2 levels, after allogeneic hematopoietic cell transplantation.

TRANSPLANT IMMUNOLOGY (2021)

Article Biophysics

Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group

Lan-Ping Xu et al.

Summary: Between 2008 and 2019, there were 58,914 hematopoietic stem cell transplantations reported in China. A focus on 2019 data shows continued growth in transplant activity, especially in haploidentical HSCT. The most common indications for allogeneic HSCT were AML and ALL, with a high proportion of multiple stem cell sources used in China. The BuCy based regimen was the most popular conditioning regimen for allogeneic HSCT.

BONE MARROW TRANSPLANTATION (2021)

Review Oncology

The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update

Xiao-hui Zhang et al.

Summary: The recent updated consensus recommendations from The Chinese Society of Hematology on allogeneic hematopoietic stem cell transplantation (allo-HSCT) include a new donor selection algorithm, encouraging salvage treatment with novel immunotherapies, and reflecting additional evidence for specific patient groups in transplantation application.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Review Immunology

Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease

Meng-Zhu Shen et al.

Summary: This meta-analysis compared the efficacy and safety of four commercially available IL-2R antagonists in the treatment of steroid-refractory aGVHD. Basiliximab and daclizumab showed higher overall response rates and complete response rates compared to inolimomab and denileukin diftitox. The study concluded that basiliximab had the highest efficacy among the IL-2R antagonists studied.

FRONTIERS IN IMMUNOLOGY (2021)

Review Hematology

Treatment and management of graft-versus-host disease: improving response and survival

Catherine Garnett et al.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)

Letter Hematology

Diagnosis and management of acute graft-versus-host disease

Fiona L. Dignan et al.

BRITISH JOURNAL OF HAEMATOLOGY (2012)

Article Biophysics

Innovative approaches to treat steroid-resistant or steroid refractory GVHD

M. Berger et al.

BONE MARROW TRANSPLANTATION (2008)